Major Players in the South Korea Dysautonomia Market | Top Companies & Insights 2026

South Korea Dysautonomia Market Overview

According to 6Wresearch, the South Korea Dysautonomia market is poised for steady expansion, driven by the country's rapidly aging population and the growing occurrence of neurodegenerative disorders. The market is boosted by South Korea's status as a global hub for clinical trials and its focus on neurological health.

Dysautonomia is a disorder that affects the autonomic nervous system, and impacts the quality of life through symptoms like orthostatic hypotension and heart rate irregularities. Initiatives to innovate and develop specialized treatments for conditions like Multiple System Atrophy and POTS, are driving the market further.

Competitive Landscape

The competitive landscape in the South Korea Dysautonomia Industry is characterized by a blend of large-scale domestic players and multinational companies optimizing South Korea's world-class medical facilities. These companies are focused on expanding their footprint by initiating strategic partnerships, conducting large-scale clinical trials for orphan drugs, and integrating digital health solutions to manage autonomic dysfunction.

Below is a list of leading players operating in the South Korea Dysautonomia Market:

1. GC Biopharma

GC Biopharma is a leader in plasma-derived protein therapeutics and rare disease treatments, providing critical supportive care for immune-related autonomic issues.

2. Hanmi Pharmaceutical Co., Ltd.

Hanmi focuses on drug development, with a robust R&D pipeline targeting neurodegenerative pathways and metabolic conditions.

3. Yuhan Corporation

Yuhan provides a comprehensive range of CNS drugs and holds significant partnerships with global giants for neurology distribution.

4. Daewoong Pharmaceutical

Daewoong is a key player in the development of neurotoxins and regenerative medicine, contributing to the management of neurological disorders.

5. SK Biopharmaceuticals

SK Biopharmaceuticals is a global leader in CNS-specific drug discovery, notably for its success in epilepsy and sleep-wake disorders.

6. Takeda Korea

Takeda maintains a dominant presence in South Korea's rare disease and neuroscience sectors, offering specialized therapies for genetic conditions.

7. Novartis Korea

Novartis is a major contributor to the market, focusing on advanced treatments for neurodegenerative diseases and multiple sclerosis.

8. HK inno.N

This company produces essential intravenous solutions and pharmaceutical treatments used in the management of cardiovascular-autonomic symptoms.

9. Boryung Pharmaceutical

Boryung is well-known for its cardiovascular portfolio, which is vital for patients requiring management of orthostatic hypotension.

10. Myung In Pharm Co., Ltd.

Myung In specializes in CNS and psychiatric medications, offering a wide array of generic and specialized drugs that support patient care in autonomic clinics.